Fact-checked by Grok 2 weeks ago

TACSTD2

TACSTD2 is a human gene located on chromosome 1p32.1 that encodes the protein trophoblast cell-surface antigen 2 (TROP2), also known as tumor-associated calcium signal transducer 2, a type I transmembrane glycoprotein functioning as a cell surface receptor that transduces intracellular calcium signals.^[1]^[2] The gene is intronless, consisting of a single exon with an open reading frame that produces a 323-amino-acid protein featuring an extracellular domain, a transmembrane region, and a short cytoplasmic tail, with homology to the epithelial cell adhesion molecule (EpCAM).^[2] TROP2 is prominently expressed in epithelial tissues, including trophoblasts and various normal epithelia, and is upregulated in numerous carcinomas such as breast, lung, and colorectal cancers, where it promotes cell proliferation, invasion, migration, and stem cell self-renewal through signaling pathways involving PKC, MAPK, and PI3K.^[1]^[3]^[4] Its overexpression correlates with tumor aggressiveness, metastasis, and poor patient prognosis across multiple cancer types, positioning TROP2 as a biomarker and therapeutic target, exemplified by antibody-drug conjugates like sacituzumab govitecan approved for treating metastatic triple-negative breast cancer.^[4]^[5] Other TROP2-targeted antibody-drug conjugates, such as datopotamab deruxtecan, have shown promising results in clinical trials for metastatic triple-negative breast cancer as of 2025.^[6] Additionally, biallelic mutations in TACSTD2 cause gelatinous drop-like corneal dystrophy (GDLD, MIM #204870), an autosomal recessive disorder marked by amyloid deposition in the cornea leading to severe vision impairment, with common mutations such as c.352C>T (Q118X) identified in affected populations.^[2] Beyond oncology and ophthalmology, studies indicate TACSTD2 upregulation in response to lung infections, particularly viral ones, suggesting roles in epithelial repair and immune modulation.^[7]

Gene

Genomic Location and Organization

The TACSTD2 gene is located on the short arm of human chromosome 1 at the p32.1 cytogenetic band, spanning the genomic coordinates 58,575,433 to 58,577,252 on the reverse strand in the GRCh38.p14 assembly.^[1]^[8] This positions it within a gene-dense region of chromosome 1, with the gene itself encompassing approximately 1.8 kilobases (kb) of genomic sequence.^[8] TACSTD2 exhibits a compact, intronless genomic organization, consisting of a single exon that encodes the full-length transcript and protein product.^[1] This structure lacks introns, a feature that simplifies its transcription and is characteristic of certain genes involved in rapid cellular responses. The promoter region upstream of the coding sequence includes CpG-rich elements that are subject to epigenetic regulation, such as DNA methylation, influencing gene expression levels.^[1]^[9] The gene is assigned the official identifier OMIM 137290 and produces a protein product cataloged under UniProt accession P09758.^[2] Orthologs of TACSTD2 are well-conserved across vertebrates, reflecting evolutionary preservation of its sequence and function; for instance, the mouse ortholog (Tacstd2) maps to chromosome 6 at position 30.88 cM and also features an intronless structure with a single exon.^[1] Sequence identity between human and mouse TACSTD2 exceeds 80% at the nucleotide level in the coding region, underscoring its functional conservation.^[1]

Expression Patterns

TACSTD2 demonstrates basal expression predominantly in epithelial tissues, including trophoblasts of the placenta, stratified squamous epithelia such as those in the skin, cervix, tongue, and pharynx, as well as various fetal tissues like the lung. According to data from the Genotype-Tissue Expression (GTEx) project (v10), median transcript per million (TPM) levels are notably high in epithelial-rich organs, with the highest expression observed in the prostate (46 TPM) and pancreas (21 TPM), followed by moderate levels in the bladder (9 TPM), and lower in the kidney cortex (4 TPM) and lung (1 TPM). The Human Protein Atlas further corroborates this pattern, showing RNA expression in the respiratory system, gastrointestinal tract, skin, and endocrine tissues, with clustering analyses indicating similarity to other epithelial-specific genes.^[10]^[11]^[12] In fetal development, TACSTD2 expression is enhanced during processes such as lung expansion, supporting epithelial maturation, and is prominently detected in trophoblast cells, which are critical for placental function. RNA-seq studies from databases like Expression Atlas reveal consistent presence in fetal epithelial structures, aligning with its role in early barrier formation. These patterns underscore TACSTD2's association with dynamic epithelial environments across developmental stages.^[7]^[13] TACSTD2 expression is upregulated in response to infections, particularly as an early epithelial barrier defense mechanism in the lungs. Transcriptomic analyses demonstrate consistent increases following exposure to diverse pathogens, including viral agents like SARS coronavirus and influenza A virus (peaking at 2–4 days post-infection with up to 20% elevation), bacterial pathogens such as Streptococcus pneumoniae, and fungal agents like Aspergillus fumigatus. This response is dose-dependent and primarily occurs in lung epithelial cells, highlighting TACSTD2's role in acute inflammatory contexts without long-term persistence in resolved infections.^[7]^[14] Regulatory mechanisms influencing TACSTD2 include microRNA-mediated control, notably by miR-125b-1, which directly targets the gene and modulates downstream signaling. In normal cellular contexts, miR-125b-1 suppresses TACSTD2 expression, thereby inhibiting activation of the mitogen-activated protein kinase (MAPK) pathway; reduced miR-125b-1 levels lead to elevated TACSTD2 transcripts. RNA-seq comparisons from healthy versus perturbed tissues, such as those in infection models, further illustrate these dynamics, with upregulated TACSTD2 correlating to altered miRNA profiles in epithelial responses.^[15]

Protein

Molecular Structure

TACSTD2 encodes TROP2, a type I transmembrane glycoprotein consisting of 323 amino acids in humans.^[16] The protein features a signal peptide of 26 amino acids at the N-terminus, followed by a large extracellular domain, a single transmembrane helix, and a short cytoplasmic tail.^[17] This architecture positions TROP2 as a cell surface receptor involved in intercellular signaling.^[18] The extracellular domain, spanning 248 amino acids (residues 27-274), is characterized by a cysteine-rich region that includes a thyroglobulin type-1 (TY) repeat domain and a putative epidermal growth factor (EGF)-like motif.^[16]^[19] These structural elements contribute to ligand binding and protein-protein interactions, with the TY repeat featuring conserved cysteine residues for disulfide bond formation and the EGF-like motif adopting a beta-sheet-rich fold.^[20] The domain also contains four N-linked glycosylation sites at asparagine residues N33, N120, N168, and N208, which modify the protein's molecular weight to 35-40 kDa and influence its stability and trafficking.^[17] The transmembrane domain comprises a 23-amino-acid alpha-helical segment that anchors TROP2 in the plasma membrane.^[20] The cytoplasmic tail, consisting of 26 amino acids (residues 298-323), is proline-rich and includes a phosphatidylinositol 4,5-bisphosphate (PIP2)-binding site as well as potential phosphorylation motifs, such as a protein kinase C (PKC) site at serine 303.^[17] These features enable intracellular interactions and regulatory modifications, including phosphorylation that may modulate calcium signaling.^[20] TROP2 exhibits structural homology to EpCAM (encoded by TACSTD1), sharing approximately 50% sequence identity and conserved TY and EGF-like domains within the EPCAM family. However, crystal structures of the TROP2 extracellular domain (PDB: 7PEE, 7E5N) reveal distinct dimerization interfaces compared to EpCAM, with TROP2 forming stable cis- and trans-dimers via overlapping hydrophobic patches in the membrane-distal region.^[21] Predicted full-length models from AlphaFold further highlight these differences, showing a more compact cytoplasmic tail conformation.^[12]

Biochemical Function

TACSTD2 encodes the TROP2 protein, a cell surface glycoprotein that functions as a calcium signal transducer, facilitating intracellular calcium mobilization upon activation. TROP2 lacks identified natural ligands and is typically activated through homodimerization or induced clustering, such as by monoclonal antibodies, which promotes its signaling capacity.^[20] This activation leads to phosphorylation of specific serine residues in its cytoplasmic tail, primarily Ser303 and Ser322, by protein kinase C α (PKC-α) and PKC-δ, initiating calcium release from intracellular stores and subsequent signal transduction.^[22] The hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) bound to the cytoplasmic tail by phospholipase C further amplifies this process, enabling TROP2 to regulate cell adhesion, migration, and proliferation through modulation of cytoskeletal dynamics and focal adhesion turnover.^[17] TROP2 interacts directly with tight junction components claudin-1 and claudin-7 via its extracellular domain, stabilizing these proteins at epithelial junctions and maintaining barrier integrity.^[19] Phosphorylation at Ser322 by PKC-α disrupts this interaction, reducing claudin-7 stability and promoting epithelial-to-mesenchymal transition-like changes that enhance cell motility while compromising junctional adhesion.^[22] These interactions underscore TROP2's role in epithelial homeostasis, where balanced signaling supports tissue integrity, but dysregulation favors migratory phenotypes. Downstream, TROP2 activates the MAPK/ERK pathway, increasing phosphorylation of ERK1/2 to drive cell cycle progression and proliferation.^[18] Additionally, regulated intramembrane proteolysis of TROP2 releases its intracellular domain, which translocates to the nucleus and stabilizes β-catenin, enhancing Wnt signaling and promoting stem cell self-renewal and hyperplasia.^[23] In tumor contexts, TROP2 overexpression amplifies these pathways, contributing to aggressive growth, though detailed mechanisms remain under investigation.^[20]

Discovery and Research History

Initial Identification

TACSTD2 encodes the transmembrane glycoprotein known as trophoblast cell-surface antigen 2 (TROP2), which was first identified in 1981 as a cell surface marker on human trophoblast cells. Researchers led by Lipinski et al. generated a panel of monoclonal antibodies by immunizing mice with the BeWo human choriocarcinoma cell line, a model for trophoblastic tissue, and screened them for reactivity against trophoblast antigens. Among the antigens defined, Trop-2 was distinguished by its specific binding to syncytiotrophoblast and cytotrophoblast cells in placental tissue sections, as well as to the immunizing BeWo cells.^[24] The naming of TROP2 as "trophoblast cell-surface antigen 2" directly stemmed from this initial observation of its expression pattern, positioning it as the second in a series of trophoblast-specific markers (following Trop-1) identified through the same monoclonal antibody approach. This discovery highlighted TROP2's role as a potential marker for invasive trophoblast cells involved in placental implantation.^[24] From its outset, TROP2 garnered attention in tumor immunology as a carcinoma-associated antigen, given the use of a choriocarcinoma-derived cell line for antibody production and the antigen's presence on malignant trophoblast cells. The original study proposed that anti-TROP2 antibodies could aid in detecting circulating fetal trophoblast cells in maternal blood and support diagnostic and therapeutic applications for choriocarcinomas and germ-cell neoplasms.^[24] Early biochemical studies characterized TROP2 as a glycoprotein, with immunoprecipitation revealing an apparent molecular weight of approximately 46 kDa under reducing conditions, consistent with a range of 40-46 kDa accounting for glycosylation variations observed across carcinoma cell lines.^[25]

Cloning and Characterization

In 1989, Linnenbach et al. identified and cloned the genomic sequence of TACSTD2 (as GA733-1) using a monoclonal antibody raised against a gastric carcinoma cell line.^[26] The human TACSTD2 gene, encoding the tumor-associated calcium signal transducer 2 (also known as TROP2 or GA733-1), was cloned in 1993 from a human placental cDNA library.^[27] Researchers screened the library using probes based on partial sequences from the related GA733-2 antigen, isolating full-length clones that revealed an open reading frame predicting a 323-amino-acid type I transmembrane glycoprotein.^[27] Sequence analysis confirmed that TACSTD2 is an intronless gene, likely arising via retroposition from the multi-exon TACSTD1 (EpCAM) gene, with which it shares approximately 50% amino acid identity in the extracellular domain.^[27] The murine ortholog, Tacstd2, was cloned in 1998 by PCR amplification using human TROP2 primers followed by screening a mouse genomic library. The full-length sequence encodes a 317-amino-acid protein exhibiting about 87% overall homology to the human TACSTD2 at the nucleotide level and high conservation in the transmembrane and cytoplasmic domains, including a potential PIP2-binding motif. This cross-species similarity supported early comparative studies on expression and function.^[28] Early characterization of TACSTD2 function involved demonstration in human cancer cells that anti-TROP2 monoclonal antibody cross-linking induced rapid intracellular calcium mobilization and downstream signal transduction events, consistent with a role as a cell surface receptor.^[29] Fluorescence in situ hybridization (FISH) mapped the TACSTD2 locus to chromosome 1p32, a region frequently altered in epithelial cancers.^[30] Linkage analyses in families with gelatinous drop-like corneal dystrophy (GDLD) mapped the gene to 1p32 and later identified pathogenic mutations.^[31] A comprehensive review in 2008 highlighted TACSTD2 as part of the epithelial cell adhesion molecule family, emphasizing its shared structural features with EpCAM/TACSTD1 and its emerging roles in calcium-dependent signaling and epithelial integrity beyond mere antigenicity.

Physiological Roles

Normal Tissue Expression

TACSTD2, encoding the TROP2 protein, exhibits high expression in placental trophoblasts, where it serves as a key surface marker facilitating trophoblast function during placental development.^[18] This expression is prominent in cytotrophoblasts and syncytiotrophoblasts, contributing to the maintenance of epithelial integrity in this specialized tissue.^[32] In fetal epithelia, TROP2 is widely distributed, particularly in developing lung and intestinal tissues, supporting proliferative and differentiative processes in embryonic epithelial layers.^[33] In adult stratified epithelia, TROP2 shows robust expression in tissues such as the skin, esophagus, and cervix, where it localizes to squamous epithelial cells, including basal and suprabasal layers.^[20] For instance, in the skin, TROP2 is detected in keratinocytes of the stratified epidermis, while in the esophagus and cervix, it marks the multilayered squamous epithelium essential for barrier protection.^[34] Conversely, TROP2 expression is low or absent in most simple epithelia under normal conditions, such as lung alveoli and kidney tubules, reflecting its preferential association with multilayered, regenerative epithelial structures rather than single-layered ones.^[35] TROP2 contributes to epithelial barrier maintenance through interactions with claudins, particularly claudin-1 and claudin-7, which stabilize tight junctions in expressing epithelia.^[18] These interactions support steady-state barrier function in stratified tissues like skin and esophagus, preventing paracellular leakage. Additionally, TROP2 is expressed in stem cell niches, such as intestinal crypts and skin basal layers, where it associates with progenitor cells possessing regenerative potential.^[17] In intestinal crypts, TROP2 marks epithelial progenitors involved in homeostasis, while in skin basal layers, it enriches for stem-like keratinocytes.^[20] In certain contexts, such as lung infections, TROP2 expression can be upregulated to aid barrier repair, though this is secondary to its baseline roles.^[7]

Developmental and Cellular Functions

TACSTD2, encoding the transmembrane glycoprotein TROP2, plays a critical role in embryonic development, particularly through its expression in invasive trophoblast cells that facilitate placental implantation and uterine decidua invasion.^[17] As a biomarker of trophoblast invasion, TROP2 supports the migratory behavior of these cells during early placentation, contributing to proper embryo implantation and placental formation.^[19] TROP2 is also expressed in the trophectoderm of preimplantation mouse and human embryos, aiding in early epithelial lineage specification.^[36] Although TACSTD2 knockout mice exhibit viable embryonic development without overt lethality, the protein's presence in trophoblasts underscores its involvement in coordinating invasion processes essential for placental establishment.^[37] In organogenesis, TROP2 regulates cell proliferation and migration within epithelial progenitors, as demonstrated in kidney development where its expression in the trunk of the ureteric duct epithelium regulates branching morphogenesis by suppressing cell migration and spreading.^[38] This function involves enhancing progenitor cell dynamics to ensure proper tissue patterning and growth during embryogenesis. TROP2's influence extends to maintaining epithelial integrity by supporting tight junction formation and apicobasal polarity in stratified epithelia, where it cooperates with EPCAM to stabilize claudins in co-expressing tissues, such as stratified epithelia, preventing barrier defects in extraintestinal tissues; TROP2 is absent in intestinal epithelia.^[39] At the cellular level, TROP2 functions as a calcium-dependent signal transducer that modulates intracellular calcium fluxes to influence epithelial cell behavior.^[17] This signaling supports tissue regeneration and stem cell self-renewal, particularly in prostate epithelium, where TROP2 proteolysis activates β-catenin pathways to drive progenitor proliferation and repair following injury.^[40] In mammary and other stratified epithelia, TROP2 similarly enriches for stem-like populations capable of self-renewal, ensuring homeostasis and regenerative capacity without disrupting normal developmental timelines.^[41]

Pathological Roles

Role in Cancer

TACSTD2, also known as TROP2, is overexpressed in over 80% of solid epithelial cancers, including breast, colorectal, lung, and prostate malignancies, where elevated expression consistently correlates with poor patient prognosis and increased tumor aggressiveness.^[18]^[17] In these cancers, TROP2 upregulation is linked to reduced overall survival rates, as observed in pancreatic cancer where overexpression occurs in 55% of cases and significantly shortens survival.^[42] Similarly, high TROP2 levels in ovarian and cervical cancers are associated with advanced disease stages and higher metastasis risk.^[43]^[18] TROP2 promotes tumor growth, invasion, and metastasis primarily through activation of key signaling pathways, including MAPK/ERK, PI3K/AKT, and Wnt/β-catenin.^[17]^[44]^[45] The MAPK pathway, particularly ERK1/2, drives cell proliferation and inhibits apoptosis, while PI3K/AKT enhances cell survival and motility, as demonstrated in oral squamous cell carcinoma models where TROP2 knockdown reduces invasion via pathway suppression.^[44]^[46] Wnt/β-catenin signaling further supports metastatic spread by regulating epithelial-mesenchymal transition (EMT) and cytoskeletal dynamics.^[45] TROP2 expression correlates strongly with cancer stem cell-like properties and chemoresistance, contributing to tumor recurrence and treatment failure.^[47]^[17] In prostate cancer, elevated TROP2 levels enhance stemness markers, promoting self-renewal and resistance to chemotherapeutic agents like docetaxel.^[47] This association extends to broader drug resistance mechanisms, where TROP2 overexpression sustains survival signaling even under therapeutic stress.^[48] A prominent example is triple-negative breast cancer (TNBC), where high TROP2 expression drives EMT by inactivating E-cadherin and upregulating mesenchymal markers, facilitating invasion and distant metastasis.^[49]^[50] In TNBC, TROP2 levels are markedly elevated compared to other subtypes, correlating with worse prognosis and increased circulating tumor cell heterogeneity.^[51]^[52] Unlike many oncogenes, TROP2 rarely harbors oncogenic mutations; instead, its upregulation in cancer typically arises from gene amplification or epigenetic mechanisms.^[53]^[54] Amplification events, such as bicistronic CYCLIN D1-TROP2 chimeras, drive aberrant expression in ovarian and breast cancers, while epigenetic modifications like promoter hypomethylation further enhance transcription.^[54]^[55]

Associations with Non-Cancerous Diseases

Biallelic loss-of-function mutations in the TACSTD2 gene cause gelatinous drop-like corneal dystrophy (GDLD), a rare autosomal recessive disorder characterized by progressive corneal amyloid deposition that leads to severe visual impairment and blindness. This condition typically manifests in early childhood with subepithelial amyloid accumulations forming mulberry-like opacities on the corneal surface, disrupting the epithelial barrier and resulting in photophobia, tearing, and eventual corneal erosion. The Q118X nonsense mutation serves as a founder allele prevalent among Japanese patients, accounting for a significant proportion of cases in that population, and leads to truncated TACSTD2 protein lacking critical transmembrane and intracellular domains essential for epithelial integrity.^[56]^[57]^[58] In polycystic kidney disease (PKD), TACSTD2 is upregulated in pre-cystic and cystic renal epithelial cells, suggesting a role in cyst initiation and expansion. This overexpression occurs early in disease pathogenesis, particularly in models of autosomal dominant PKD, where it is absent or low in normal kidney tissue but markedly elevated in cyst-lining epithelia, potentially promoting aberrant cell signaling and proliferation that drives cyst growth.^[59]^[60] TACSTD2 expression is induced rapidly in lung epithelia during viral or bacterial infections, acting as an early protective response to repair and reinforce the airway barrier compromised by pathogens. This upregulation helps maintain intercellular junctions and prevent fluid leakage or further invasion, contributing to epithelial regeneration in infected tissues.^[61]^[7]

Clinical Applications

Diagnostic Uses

TACSTD2, encoding the TROP2 protein, serves as a diagnostic biomarker in various epithelial malignancies through assessment of its expression levels via immunohistochemistry (IHC) on tumor biopsies. High TROP2 expression detected by IHC correlates with tumor aggressiveness and poor prognosis in head and neck squamous cell carcinoma (HNSCC), where membranous staining in invasive tumor cells predicts reduced overall survival and increased metastatic potential.^[62]^[63] Similarly, elevated TROP2 levels in biopsies from oral squamous cell carcinoma, a subset of HNSCC, are associated with advanced disease stages and unfavorable outcomes, enabling risk stratification for patients.^[64] This overexpression pattern, as detailed in pathological roles, underscores TROP2's utility in prognostic evaluation without altering its biological implications. Circulating forms of TROP2, including soluble protein and TROP2-positive extracellular vesicles or circulating tumor cells (CTCs), have emerged as non-invasive serum biomarkers for monitoring epithelial cancers such as breast, prostate, and esophageal carcinomas. Detection of elevated TROP2 on CTCs via liquid biopsy techniques shows high expression in triple-negative breast cancer, correlating with disease burden and enabling early identification of metastatic spread.^[65] In prostate cancer, quantification of TROP2-carrying extracellular vesicles in serum provides a potential indicator of tumor progression, with levels distinguishable from healthy controls.^[66] Serological assays for TROP2 in esophageal squamous cell carcinoma further support its role as a circulating marker for epithelial tumor detection and recurrence monitoring.^[67] Genetic testing for TACSTD2 mutations is essential for diagnosing gelatinous drop-like corneal dystrophy (GDLD), a rare autosomal recessive disorder characterized by corneal amyloid deposition. Pathogenic variants, including missense, nonsense, and frameshift mutations, disrupt TROP2 function and lead to protein mislocalization, confirming the diagnosis through direct sequencing of the TACSTD2 gene on chromosome 1p32.^[68] Founder mutations, such as the homozygous Q118X nonsense variant prevalent in Japanese populations and the C66X mutation in Iranian cohorts, facilitate targeted screening in high-risk ethnic groups, with multiple pedigrees showing homozygous inheritance patterns.^[69]^[70] These tests enable presymptomatic identification and genetic counseling, distinguishing GDLD from other corneal dystrophies. Emerging applications of TROP2 in liquid biopsies hold promise for early detection of colorectal cancer precursors, leveraging its overexpression in epithelial tumors for CTC isolation. Anti-TROP2 antibodies effectively capture CTCs from blood samples, as demonstrated in solid tumors where TROP2 expression mirrors epithelial-mesenchymal transition features relevant to colorectal progression.^[71] In colorectal adenocarcinoma, high TROP2 positivity in tumor tissues associates with lymph node metastases and poor differentiation, suggesting its potential integration into liquid biopsy panels for monitoring adenoma-to-carcinoma transition, though clinical validation for adenoma-specific detection remains ongoing.^[72]

Therapeutic Targeting

Therapeutic targeting of TACSTD2, also known as TROP2, has primarily focused on antibody-drug conjugates (ADCs) that exploit its overexpression in various solid tumors, particularly in oncology. Sacituzumab govitecan (Trodelvy), an ADC comprising a humanized anti-TROP2 monoclonal antibody conjugated to the topoisomerase I inhibitor SN-38 via a hydrolyzable linker, received accelerated FDA approval in April 2020 for metastatic triple-negative breast cancer (mTNBC) after at least two prior therapies, based on the phase II ASCENT trial demonstrating an objective response rate of 35% and median progression-free survival of 5.6 months.^[73] This approval was converted to regular in April 2021 following confirmatory data, and expanded in February 2023 to hormone receptor-positive, HER2-negative breast cancer after endocrine therapy and at least two systemic treatments.^[74]^[73] An accelerated approval for locally advanced or metastatic urothelial cancer was granted in April 2021 but withdrawn in October 2024 after the phase III TROPiCS-04 trial failed to meet its primary endpoint of overall survival.^[75]^[76] On December 17, 2024, the FDA granted breakthrough therapy designation to sacituzumab govitecan for second-line treatment of extensive-stage small cell lung cancer after failure of platinum-based chemotherapy, based on interim data from the phase III TROPiCS-03 trial.^[77] The mechanism of sacituzumab govitecan involves the antibody binding to cell-surface TROP2, triggering receptor-mediated internalization and lysosomal degradation, which releases SN-38 to inhibit topoisomerase I and induce DNA damage preferentially in TROP2-expressing tumor cells.^[78]^[79] This bystander effect allows the membrane-permeable SN-38 to diffuse to neighboring cells, addressing tumor heterogeneity. Datopotamab deruxtecan, another TROP2-directed ADC with a topoisomerase I inhibitor payload linked via a cleavable tetrapeptide-based linker, received accelerated FDA approval on January 17, 2025, for unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer previously treated with endocrine therapy and at least one systemic therapy, based on the phase III TROPION-Breast01 trial, and on June 23, 2025, for previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supported by pooled data from TROPION-Lung01 and TROPION-Lung05 trials showing an objective response rate of 36.6%.^[80]^[81]^[82] Multiple phase III trials are ongoing for datopotamab deruxtecan in NSCLC, including combinations with pembrolizumab and platinum chemotherapy.^[83] Beyond ADCs, investigational approaches include bispecific antibodies and chimeric antigen receptor (CAR) therapies targeting TROP2. A TROP2/CD3 bispecific antibody has shown potent antitumor activity in preclinical models with reduced on-target off-tumor toxicity due to engineered affinity tuning.^[84] CAR-T cells directed against TROP2 are in early-phase and preclinical development for solid tumors, including NSCLC, where they demonstrate efficacy against persister cells and resistance to ADCs.^[85] CAR-NK cells directed against TROP2 are in early-phase trials (phase I/II) for solid tumors, such as high-grade serous ovarian cancer (NCT05922930).^[86] Additional ADCs and combination strategies are under evaluation in trials for urothelial, endometrial, and other TROP2-high cancers, including sacituzumab govitecan in pretreated endometrial carcinoma (ASCENT-GYN-01).^[87] Challenges in TROP2 targeting include acquired resistance through genomic alterations, such as the TROP2 T256R missense mutation, which impairs plasma membrane localization and reduces antibody binding, as observed in post-treatment TNBC biopsies.^[88]^[89] Heterogeneous TROP2 expression across tumors can also limit efficacy, necessitating patient selection via biomarkers like quantitative continuous scoring.^[90] In non-oncologic contexts, TACSTD2 mutations cause gelatinous drop-like corneal dystrophy (GDLD), a rare autosomal recessive disorder leading to corneal opacification. Preclinical studies using immortalized corneal cells from GDLD patients demonstrate that transduction with wild-type TACSTD2 normalizes tight junction proteins like claudin-1 and claudin-7, restoring barrier function and suggesting potential for gene therapy approaches.^[91]^[92]

References

[1]
TACSTD2 tumor associated calcium signal transducer 2 [ (human)]
Sep 22, 2025 · This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals.
[2]
Entry - *137290 - TUMOR-ASSOCIATED CALCIUM SIGNAL ... - OMIM
The TACSTD2 gene encodes a type I transmembrane protein with a structure consistent with a cell signal transduction function (summary by Ren et al., 2002).
[3]
Trop2: Jack of All Trades, Master of None - PubMed - NIH
Nov 11, 2020 · Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was ...<|separator|>
[4]
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a ...
It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes ...Missing: function | Show results with:function
[5]
Trop2-Targeted Molecular Imaging in Solid Tumors - PubMed - NIH
Dec 2, 2024 · Trophoblast cell surface antigen 2 (Trop2), a transmembrane glycoprotein, plays a dual role in physiological and pathological processes.
[6]
TACSTD2 upregulation is an early reaction to lung infection - Nature
Jun 10, 2022 · We demonstrate that TACSTD2 level consistently increases in lungs infected with miscellaneous, but mainly viral pathogens.
[7]
https://www.nature.com/articles/s41598-022-13637-9
[8]
DNA demethylation and tri-methylation of H3K4 at the TACSTD2 ...
Feb 1, 2024 · Our data provide novel evidence for promoter demethylation and simultaneous gains of the active histone mark H3K4me3 across CpG-rich sequences.Missing: NCBI | Show results with:NCBI
[9]
GTEx Portal
### Summary of TACSTD2 Median TPM Expression Levels
[10]
TACSTD2 protein expression summary - The Human Protein Atlas
Full gene name according to HGNC. Tumor associated calcium signal transducer 2. Gene name i. Official gene symbol, which is typically a short form of ...
[11]
TACSTD2 Gene - GeneCards | TACD2 Protein
This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals.
[12]
Trophoblast organoids as a model for maternal-fetal interactions ...
May 13, 2020 · PC2 highlights epithelial genes (CLDN3, TACSTD2 and KRT23), specific for trophoblast compared to other placental cells (Extended Data Fig. 4b).
[13]
https://pmc.ncbi.nlm.nih.gov/articles/PMC7220805/
[14]
Loss of miR-125b-1 contributes to head and neck cancer ... - PubMed
Feb 6, 2014 · We report that miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression.
[15]
p09758 · tacd2_human - UniProt
A form of lattice corneal dystrophy, a class of inherited stromal amyloidoses characterized by pathognomonic branching lattice figures in the cornea.
[16]
Trop2 and its overexpression in cancers: regulation and clinical ...
The gene that codes for Trop2 is called Tacstd2, Tumor-associated calcium signal transducer 2, and it is found on chromosome 1p32 [2]. It is about 35 kDa, with ...
[17]
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a ...
Jun 22, 2018 · In HNSCC, TROP-2's gene (TACSTD2) has been identified as the target of microRNA, miR-125-1, resulting in dysfunction of the MAPK pathway [60].
[18]
Trop2: From development to disease - McDougall
Dec 19, 2014 · Trop2 was first discovered as a biomarker of invasive trophoblast cells. Since then most research has focused on its role in tumourigenesis.<|control11|><|separator|>
[19]
Trop2: Jack of All Trades, Master of None - MDPI
In humans, the intronless TACSTD2 gene is located on chromosome 1 in 1p32 locus [3]. ... Low expression of Trop2 in lung adenocarcinomas was attributed to the DNA ...<|control11|><|separator|>
[20]
7PEE: Crystal structure of extracellular part of human Trop2
Oct 13, 2021 · Trop2 Forms a Stable Dimer with Significant Structural Differences within the Membrane-Distal Region as Compared to EpCAM. · Total Structure ...Missing: AlphaFold | Show results with:AlphaFold
[21]
Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by ...
Jul 26, 2019 · Our findings provide evidence that Trop-2 is phosphorylated at Ser-322 by PKCα/δ and that this phosphorylation enhances cell motility and decreases claudin-7 ...Missing: transduction | Show results with:transduction
[22]
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling
### Summary of TROP2 Biochemical Function from https://genesdev.cshlp.org/content/26/20/2271.full
[23]
Human trophoblast cell-surface antigens defined by monoclonal ...
A series of monoclonal antibodies has been raised against the human choriocarcinoma cell-line, BeWo. Four antigens, Trop-1, -2, -3, and -4, are defined on ...
[24]
Biochemical characterization of Trop-2, a cell surface ... - PubMed
... glycoprotein, with an apparent molecular weight of 57 kD in non-reducing conditions. A weaker band of 38 kD is often co-precipitated with the 57 kD form in ...Missing: Lipinski 1990
[25]
Retroposition in a family of carcinoma-associated antigen genes
This study describes the mechanism of evolution of the GA733-1 and GA733-2 genes. A full-length cDNA clone for GA733-1 was obtained by screening a human ...Missing: TACSTD2 | Show results with:TACSTD2
[26]
Human Trop-2 is a tumor-associated calcium signal transducer
Our findings show that Trop-2 transduces an intracellular calcium signal, are consistent with the hypothesis that it acts as a cell surface receptor.Missing: Ren 2002
[27]
Assignment of TACSTD1 (alias TROP1, M4S1) to human ... - PubMed
Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situMissing: FISH | Show results with:FISH
[28]
Unveiling the placental secrets: Exploring histopathological changes ...
Sep 2, 2024 · Trophoblast cell surface antigen (TROP2) is a type I transmembrane glycoprotein identified in placental trophoblast cells that plays a critical ...
[29]
The oncogene Trop2 regulates fetal lung cell proliferation - PubMed
Trop2 expression was regulated by fetal lung expansion, but not by glucocorticoids. It was increased nearly threefold by 36 h of increased fetal lung expansion ...
[30]
A focused review on Trop-2-based antibody-drug conjugates and ...
Trop-2 expression was originally described in trophoblasts (placenta) and fetal tissues (e.g. lungs). Its expression was subse-quently described in the ...
[31]
Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor ...
Trop2 is a cell-surface glycoprotein reported to be overexpressed in various types of adenocarcinomas with minimal expression in normal tissues.
[32]
Tacstd2 MGI Mouse Gene Detail - MGI:1861606 - tumor-associated ...
Mice homozygous for a knock-out allele exhibit normal development, life expectancy and tumorigenesis.
[33]
https://pubmed.ncbi.nlm.nih.gov/21743029/
[34]
EPCAM and TROP2 share a role in claudin stabilization and ...
These findings identify overlapping functions of EPCAM and TROP2 as regulators of epithelial development in both intestinal and extraintestinal tissues.<|control11|><|separator|>
[35]
Regulated proteolysis of Trop2 drives epithelial hyperplasia and ...
The cell surface protein Trop2 is expressed on immature stem/progenitor-like cells and is overexpressed in many epithelial cancers. However the biological ...Trop2 Regulates Self-Renewal... · Trop2 Is Processed By... · Trop2 Is Cleaved By RipMissing: fetal | Show results with:fetal
[36]
Trop2 identifies a subpopulation of murine and human prostate ...
Dec 30, 2008 · Trop2 subfractionates the basal cells into 2 populations, both of which express characteristic basal cell markers by quantitative PCR.
[37]
High expression of TROP2 correlates with poor prognosis ... - Nature
Sep 23, 2008 · The human trophoblast cell-surface antigen, TROP2 (also termed GA733-1), is a transmembrane glycoprotein found to be expressed at high levels by ...<|control11|><|separator|>
[38]
Targeting Trop-2 in cancer: Recent research progress and clinical ...
The cytoplasmic tail of Trop-2 has a HIKE domain and contains serine residues that can be phosphorylated by protein kinase C (PKC) (S303) and a ...Missing: motifs | Show results with:motifs
[39]
Trop2 expression contributes to tumor pathogenesis by activating ...
This study provides new evidence that Trop2 contributes to tumor pathogenesis at least in part by activating the ERK1/2 MAPK pathway which has important ...
[40]
TROP2 Inhibitors - Cancer Therapeutics - BOC Sciences
TROP2's role in multiple cancer progression pathways such as Wnt/β-catenin, MAPK, and PI3K/AKT establishes it as a promising therapeutic target. Sacituzumab ...Trop2 Function In Normal... · Trop2 Signaling Pathways · Trop2 As A Therapeutic...Missing: via | Show results with:via<|separator|>
[41]
TROP2 increases growth and metastasis of human oral squamous ...
Oct 21, 2019 · These results suggest that TROP2 induces cell growth, migration and invasion through activation of the PI3K/Akt signaling pathway in OSCC cells.
[42]
The Relationship between Trop-2, Chemotherapeutic Drugs ... - NIH
Therefore, evidence indicates, at least in prostate cancer, that Trop-2 may be associated with chemoresistant relapse through increased stemness.
[43]
The Relationship between Trop-2, Chemotherapeutic Drugs, and ...
Dec 20, 2023 · We conclude that there is a clear role for Trop-2 in some specific chemoresistance events. On the other hand, there is no clear evidence for its ...
[44]
TROP2 is highly expressed in triple-negative breast cancer CTCs ...
Jan 10, 2024 · Furthermore, TROP2 can promote the migration and invasion of TNBC cells by upregulating EMT markers. The specificity and potential of TROP2 as ...
[45]
101P E-cadherin inactivation by Trop-2 drives EMT-less metastatic ...
We have identified functional inactivation of E-cadherin by Trop-2 as a pivotal driver of EMT-less metastatic diffusion in TNBC.
[46]
TROP2 is highly expressed in triple-negative breast cancer CTCs ...
Jan 9, 2024 · TROP2 is a transmembrane glycoprotein and calcium signaling transducer, which is limited expressed in normal human tissues and overexpressed ...
[47]
Correlation of TROP-2 expression with clinical–pathological ... - Nature
Dec 28, 2022 · triple-negative breast cancer (TNBC). TROP-2 expression was ... Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.
[48]
A non-mutated TROP2 fingerprint in cancer genetics - PMC
Jun 29, 2023 · These findings suggest that mutagenic and the TROP2 non-mutagenic pathways deeply intertwine in driving transformed cell growth and malignant progression of ...
[49]
A Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a ...
Sep 30, 2008 · FISH analysis of metaphase spreads of OVCA-432 or MCF-7 cells localized the TROP2 (TACSTD2) gene to 1p32 and the CYCLIN D1 gene to 11q13, i.e., ...
[50]
Epigenetically upregulating TROP2 and SLFN11 enhances ... - NIH
Aug 11, 2023 · Upregulation of TROP2 expression enhances antitumor efficacy of sacituzumab govitecan. Our internalization results showed that SG binds to cell ...<|control11|><|separator|>
[51]
204870 - CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD
Gelatinous drop-like corneal dystrophy is an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.
[52]
A novel mutation in gelatinous drop-like corneal dystrophy ... - Nature
Jul 11, 2019 · We identified a novel mutation of the tumor-associated calcium signal transducer 2 (TACSTD2) gene in a Japanese patient with gelatinous drop-like corneal ...
[53]
Gelatinous Drop-Like Corneal Dystrophy - EyeWiki
Jun 20, 2025 · ... GDLD with the Q118X mutation being the most commonly detected. ... like corneal dystrophy (GDLD) of a patient with TACSTD2 gene mutation.Disease Entity · General Pathology · Diagnosis · Differential diagnosis
[54]
The Tumor-Associated Calcium Signal Transducer 2 (TACSTD2 ...
The Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) oncogene is upregulated in pre-cystic epithelial cells revealing a new target for polycystic kidney ...Missing: flux | Show results with:flux
[55]
The Tumor-Associated Calcium Signal Transducer 2 (TACSTD2 ...
Dec 4, 2023 · Our finding that Tacstd2 is highly expressed in cysts, but not normal tissue, suggests that it should be explored as a candidate for drug development in PKD.Missing: Ren et 2002 flux
[56]
TACSTD2 upregulation is an early reaction to lung infection - PubMed
Jun 10, 2022 · Increase in TACSTD2 expression may represent a mechanism to maintain/restore epithelial barrier function and contribute to regeneration process ...Missing: bacterial | Show results with:bacterial
[57]
Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis ...
Dec 22, 2021 · We studied the prognostic influence of Trop-2 protein expression on OSCC patients' survival. The cohort comprised n = 229 OSCC patients with available archived ...Missing: biopsies aggressiveness HNSCC
[58]
High expression of TROP2 is correlated with poor prognosis of oral ...
TROP2 expression promotes fetal lung growth and ... Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage.3. Results · 3.3. Trop2 Expression Is... · 3.4. High Trop2 Expression...
[59]
Overexpression of TROP2 is associated with poor survival of patients...
The correlation between TROP2 and tumor aggressiveness has implied it could be a prognostic indicator. However, the roles of TROP2 and their underlying ...Missing: biopsies | Show results with:biopsies
[60]
TROP2 is highly expressed in triple-negative breast cancer CTCs ...
The tumor antigen TROP2, encoded by the TACSTD2 gene, is one of the most significantly differentially expressed proteins between normal and tumor tissues, ...
[61]
Extracellular Vesicles in Serum Carry Trop2 Protein as a Potential ...
Sep 23, 2025 · This study demonstrates the isolation and quantification of Trop2-carrying extracellular vesicles (EV-Trop2) in prostate cancer serum.
[62]
https://pubmed.ncbi.nlm.nih.gov/35008509/
[63]
A novel TACSTD2 mutation identified in two Chinese brothers with ...
Aug 14, 2009 · To identify the molecular defect causing gelatinous drop-like corneal dystrophy (GDLD) in two Chinese brothers and report the morphological ...Missing: testing | Show results with:testing
[64]
Four Mutations (Three Novel, One Founder) in TACSTD2 among ...
Four disease-associated mutations in TACSTD2, C66X, F114C, L186P, and E227K, were identified among the 13 Iranian GDLD pedigrees studied. Three of the mutations ...
[65]
Chromosomal sharing in atypical cases of gelatinous drop-like ...
Nov 5, 2010 · Genetic analysis revealed that all the patients possessed a homozygous Q118X mutation in TACSTD2, a major founder mutation in Japanese GDLD.
[66]
Expression and Therapeutic Targeting of TROP-2 in Treatment ...
However, TROP-2 is overexpressed in many human epithelial cancers, including prostate, breast, gastric, colorectal, pancreatic, cervical, urothelial, and ...
[67]
TROP2 Represents a Negative Prognostic Factor in Colorectal ... - NIH
Trophoblastic cell surface antigen 2 (TROP2) is a membrane glycoprotein overexpressed in many solid tumors with a poor prognosis, including intestinal neoplasms ...
[68]
FDA approves sacituzumab govitecan-hziy for HR-positive breast ...
Feb 3, 2023 · On February 3, 2023, the Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for ...Missing: TACSTD2 TROP2 targeting
[69]
FDA grants regular approval to sacituzumab govitecan for triple ...
Apr 8, 2021 · On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for ...Missing: TACSTD2 TROP2 targeting
[70]
FDA grants accelerated approval for sacituzumab govitecan
Nov 25, 2024 · FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer ... On April 13, 2021, the Food and Drug Administration ...
[71]
Gilead Provides Update on U.S. Indication for Trodelvy® in ...
Oct 18, 2024 · Trodelvy was granted accelerated approval for metastatic urothelial cancer in 2021 based on tumor response rate and duration of response ...
[72]
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38
Subsequently, we determined the molecular properties of the antigen bound by RS7 as a 46-kDa ... Trop2: A possible therapeutic target for late stage epithelial ...
[73]
Mechanism of Action (MOA) TRODELVY® (sacituzumab govitecan ...
TRODELVY is the only Trop-2–directed ADC to deliver the potent cytotoxic activity of the SN-38 TOPO1 inhibitor1-3. With its SN-38 payload and CL2A linker, ...
[74]
FDA grants accelerated approval to datopotamab deruxtecan-dlnk
Jun 23, 2025 · On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults.
[75]
Results From the Phase II TROPION-Lung05 Study
Jan 6, 2025 · Trophoblast cell-surface antigen-2 (TROP2) is broadly expressed in various tumor types, including NSCLC. Datopotamab deruxtecan (Dato-DXd) is an ...
[76]
Three Phase 3 Trials of Datopotamab Deruxtecan-Based ...
Oct 30, 2024 · The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato- DXd)-based ...
[77]
Abstract 3212: Development of a Trop2/CD3 bispecific antibody with ...
Mar 22, 2024 · Our novel Trop2/CD3 bispecific antibody not only showed potent anti-tumor activity, but also demonstrated a lower risk of on-target off-tumor ...
[78]
NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced ...
Inclusion Criteria: Ovarian Cancer: Subjects must have a histology confirming diagnosis of high grade serous ovarian/peritoneal/fallopian tube cancer with ...Missing: bispecific T
[79]
TROP2 Directed CAR T in NSCLC as a Strategy for Eradicating ...
Dec 12, 2023 · Our goal is to demonstrate that TROP2 directed CAR-T cell therapy is effective in NSCLC, and can eradicate disease in a more durable fashion.
[80]
ASCENT-GYN-01 Trial of Sacituzumab Govitecan Aims to Validate ...
Sep 26, 2025 · Sacituzumab govitecan has already demonstrated significant activity in other solid tumors, and it is FDA approved for metastatic triple-negative ...
[81]
Parallel Genomic Alterations of Antigen and Payload Targets ...
Acquired resistance to the antibody–drug conjugate sacituzumab govitecan can arise through genomic alterations affecting either the antigen (TROP2) or the ...
[82]
Mechanism of Resistance to Sacituzumab Govitecan in TNBC ...
Apr 12, 2022 · Sacituzumab govitecan is an antibody–drug conjugate (ADC) that makes use of an anti-TROP2 monoclonal antibody to guide SN-38, ...
[83]
Novel computational pathology-based TROP2 biomarker for ...
Sep 8, 2024 · In patients with TROP2-QCS biomarker positive tumours, datopotamab deruxtecan demonstrated a meaningfully greater magnitude of efficacy versus ...
[84]
Investigation of Gene Therapy Using Immortalized Cells Derived ...
... TACSTD2 gene normalizes the disease situation of GDLD corneas to some extent, thus indicating that gene therapy may prove to be a promising treatment for GDLD.
[85]
A New in Vitro Model of GDLD by Knocking Out TACSTD2 ... - PubMed
Dec 21, 2018 · We established an in vitro disease model of GDLD by knocking out TACSTD2 and its paralogous gene, EpCAM, in HCE-T cells.